Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern

Canagliflozin (Invokana) is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor that was first introduced in 2013 for the treatment of type 2 diabetes mellitus (DM). Though not FDA approved yet, its use in type 1 DM has been justified by the fact that its mechanism of action is independent...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Case Rep Crit Care
Main Authors: Gelaye, Alehegn, Haidar, Abdallah, Kassab, Christina, Kazmi, Syed, Sinha, Prabhat
Format: Artigo
Sprog:Inglês
Udgivet: Hindawi Publishing Corporation 2016
Fag:
Case Report
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4819091/
https://ncbi.nlm.nih.gov/pubmed/27088018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/1656182
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker